1. By analyzing data from our clinical practice, the Author has demonstrated that there may be a relationship between thrombotic events and IL-6 levels in some

gastrointestinal patients (31).

 

2. However, analysis of data also from the clinic has shown that there is no association between thrombocytosis and survival in prostate cancer patients (35).

However, because of the many correlations found in the literature and the Author’s practice (see Introduction), we were curious about the role of PLT-s in the

interaction with tumor tissue. Is there a possible direct tumor/PLT binding? This question can be investigated in vivo using SPECT-labelled PLT-s.

 

3. Therefore, we have developed a completely new, different method for PLT marking (28). PLT-s were directly labeled using 99mTc-HYNIC-Duramycin complex, and

with this prediction, it is now possible to monitor PLT-s in vivo using SPECT/CT imaging. This method is aimed at the possible overall use of PLT imaging with SPECT to further answer PLT distribution-related questions in vascular, tumor, immune, and aging biology. Our intention was not expressly the application of the radiolabeled PLT-s for any detection of thrombi but rather the report on the labeling and stability and the SPECT imaging possibility of the so-radiolabeled PLT-s for any biological purpose. The performed small-animal in vivo SPECT/CT investigation revealed good in vivo stability of the labeled PLT-s, which adumbrates the possible clinical applicability of the PLT-radiolabeling procedure with 99mTc-HYNIC-Duramycin.

 

4. Other previously unpublished results also confirm the usefulness of the method. These unpublished images show that the labeled PLT-s reach the tumor 22 hours after administration, certainly in the ZR-75-1 breast tumor cell line.